CD137 enhancement of HPV positive head and neck squamous cell carcinoma tumor clearance

Vaccines

Volumn 2, Issue 4, 2014, Pages 841-853

  Lucido, Christopher T ^a   Vermeer, Paola D ^a   Wieking, Bryant G ^a   Vermeer, Daniel W ^a   Lee, John H ^a  

^a SANFORD RESEARCH   (United States)

Author keywords

CD137; HPV; Immune; Mouse; Squamous

Indexed keywords

ANTIBODY; CD137 ANTIBODY; CD137 ANTIGEN; CISPLATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; GENE AMPLIFICATION; GENE TRANSFER; GENETIC TRANSFECTION; HEAD AND NECK SQUAMOUS CELL CARCINOMA; IMMUNOFLUORESCENCE TEST; MALE; MOLECULAR CLONING; MOUSE; NONHUMAN; ONCOLOGICAL PARAMETERS; POLYACRYLAMIDE GEL ELECTROPHORESIS; PROTEIN EXPRESSION; TUMOR CLEARANCE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VOLUME; WART VIRUS; WESTERN BLOTTING; X RAY;

EID: 85016854953     PISSN: None     EISSN: 2076393X     Source Type: Journal    
DOI: 10.3390/vaccines2040841     Document Type: Article

References (34)

1. Prince, A.; Aguirre-Ghizo, J.; Genden, E.; Posner, M.; Sikora, A. Head and neck squamous cell carcinoma: New translational therapies. Mt. Sinai J. Med. 2010, 77, 684-699.
2. Shiboski, C.H.; Schmidt, B.L.; Jordan, R.C. Tongue and tonsil carcinoma: Increasing trends in the U.S. population ages 20-44 years. Cancer 2005, 103, 1843-1849.
3. Hammarstedt, L.; Dahlstrand, H.; Lindquist, D.; Onelov, L.; Ryott, M.; Luo, J.; Dalianis, T.; Ye, W.; Munck-Wikland, E. The incidence of tonsillar cancer in Sweden is increasing. Acta Otolaryngol. 2007, 127, 988-992.
4. Spanos, W.C.; Nowicki, P.; Lee, D.W.; Hoover, A.; Hostager, B.; Gupta, A.; Anderson, M.E.; Lee, J.H. Immune response during therapy with cisplatin or radiation for human papillomavirus-related head and neck cancer. Arch. Otolaryngol. Head Neck Surg. 2009, 135, 1137-1146.
5. Williams, R.; Lee, D.W.; Elzey, B.D.; Anderson, M.E.; Hostager, B.S.; Lee, J.H. Preclinical models of HPV+ and HPV- HNSCC in mice: An immune clearance of HPV+ HNSCC. Head Neck 2009, 31, 911-918.
6. Vesely, M.D.; Kershaw, M.H.; Schreiber, R.D.; Smyth, M.J. Natural innate and adaptive immunity to cancer. Annu. Rev. Immunol. 2011, 29, 235-271.
7. Schreiber, R.D.; Old, L.J.; Smyth, M.J. Cancer immunoediting: Integrating immunity's roles in cancer suppression and promotion. Science 2011, 331, 1565-1570.
8. Yaguchi, T.; Sumimoto, H.; Kudo-Saito, C.; Tsukamoto, N.; Ueda, R.; Iwata-Kajihara, T.; Nishio, H.; Kawamura, N.; Kawakami, Y. The mechanisms of cancer immunoescape and development of overcoming strategies. Int. J. Hematol. 2011, 93, 294-300.
9. Seliger, B. Strategies of tumor immune evasion. BioDrugs 2005, 19, 347-354.
10. Shiao, S.L.; Coussens, L.M. The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplas. 2010, 15, 411-421.
11. Curran, M.A.; Kim, M.; Montalvo, W.; Al-Shamkhani, A.; Allison, J.P. Combination CTLA-4 blockade and 4-1BB activation enhances tumor rejection by increasing T-cell infiltration, proliferation, and cytokine production. PLoS One 2011, 6, e19499.
12. Adler, A.J.; Vella, A.T. Betting on improved cancer immunotherapy by doubling down on CD134 and CD137 co-stimulation. Oncoimmunology 2013, 2, e22837.
13. Vermeer, D.W.; Spanos, W.C.; Vermeer, P.D.; Bruns, A.M.; Lee, K.M.; Lee, J.H. Radiation-induced loss of cell surface CD47 enhances immune-mediated clearance of human papillomavirus-positive cancer. Int. J. Cancer 2013, 133, 120-129.
14. Vinay, D.S.; Kwon, B.S. Immunotherapy of cancer with 4-1BB. Mol. Cancer Ther. 2012, 11, 1062-1070.
15. Vinay, D.S.; Kwon, B.S. Role of 4-1BB in immune responses. Semin. Immunol. 1998, 10, 481-489.
16. Melero, I.; Shuford, W.W.; Newby, S.A.; Aruffo, A.; Ledbetter, J.A.; Hellstrom, K.E.; Mittler, R.S.; Chen, L. Monoclonal antibodies against the 4-1BB T-cell activation molecule eradicate established tumors. Nat. Med. 1997, 3, 682-685.
17. + murine squamous cell carcinoma and the requirements of co-stimulatory molecules on tumour and host cells. Immunology 2000, 101, 541-547.
18. Kim, Y.; Strehl, J.W.; Gorschluter, M.; Ziske, C.; Schmidt-Wolf, I.G. Prevention of lethal tumor growth and generation of long-lasting immunity in vivo using CD137L and interleukin-12 gene transfer. In Vivo 2008, 22, 337-343.
19. Sznol, M.; Hodi, F.S.; Margolin, K.; McDermott, D.F.; Ernstoff, M.S.; Kirkwood, J.M.; Wojtaszek, C.; Feltquate, D.; Logan, T. Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA). J. Clin. Oncol. 2008, 26, Abstract 3007.
20. Mittler, R.S.; Bailey, T.S.; Klussman, K.; Trailsmith, M.D.; Hoffmann, M.K. Anti-4-1BB monoclonal antibodies abrogate T cell-dependent humoral immune responses in vivo through the induction of helper T cell anergy. J. Exp. Med. 1999, 190, 1535-1540.
21. Sun, Y.; Chen, J.H.; Fu, Y. Immunotherapy with agonistic anti-CD137: Two sides of a coin. Cell. Mol. Immunol. 2004, 1, 31-36.
22. Hellstrom, K.E.; Hellstrom, I. Therapeutic vaccination with tumor cells that engage CD137. J. Mol. Med. 2003, 81, 71-86.
23. + T-cell-dependent tumor eradication and decreases risk of toxic side effects. Clin. Cancer Res. 2013, 19, 5381-5389.
24. Fransen, M.F.; Sluijter, M.; Morreau, H.; Arens, R.; Melief, C.J. Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin. Cancer Res. 2011, 17, 2270-2280.
25. +-dependent systemic and memory responses. Cancer Immunol. Immunother. 2012, 61, 549-560.
26. + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 2013, 73, 1547-1558.
27. Hoover, A.C.; Strand, G.L.; Nowicki, P.N.; Anderson, M.E.; Vermeer, P.D.; Klingelhutz, A.J.; Bossler, A.D.; Pottala, J.V.; Hendriks, W.J.; Lee, J.H. Impaired PTPN13 phosphatase activity in spontaneous or HPV-induced squamous cell carcinomas potentiates oncogene signaling through the MAP kinase pathway. Oncogene 2009, 28, 3960-3970.
28. Wieking, B.G.; Vermeer, D.W.; Spanos, W.C.; Lee, K.M.; Vermeer, P.; Lee, W.T.; Xu, Y.; Gabitzsch, E.S.; Balcaitis, S.; Balint, J.P., Jr.; et al. A non-oncogenic HPV 16 E6/E7 vaccine enhances treatment of HPV expressing tumors. Cancer Gene Ther. 2012, 19, 667-674.
29. Coppock, J.D.; Wieking, B.G.; Molinolo, A.A.; Gutkind, J.S.; Miskimins, W.K.; Lee, J.H. Improved clearance during treatment of HPV-positive head and neck cancer through mTOR inhibition. Neoplasia 2013, 15, 620-630.
30. Shi, W.; Siemann, D.W. Augmented antitumor effects of radiation therapy by 4-1BB antibody (BMS-469492) treatment. Anticancer Res. 2006, 26, 3445-3453.
31. Yurkovetsky, Z.R.; Shurin, G.V.; Barry, D.A.; Schuh, A.C.; Shurin, M.R.; Robbins, P.D. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. J. Gene Med. 2006, 8, 129-137.
32. Ye, J.; Li, L.; Zhang, Y.; Zhang, X.; Ren, D.; Chen, W. Recombinant Salmonella-based 4-1BBL vaccine enhances T cell immunity and inhibits the development of colorectal cancer in rats: In vivo effects of vaccine containing 4-1BBL. J. Biomed. Sci. 2013, 20, doi:10.1186/1423-0127-20-8.
33. Badoual, C.; Hans, S.; Merillon, N.; van Ryswick, C.; Ravel, P.; Benhamouda, N.; Levionnois, E.; Nizard, M.; Si-Mohamed, A.; Besnier, N.; et al. PD-1-expressing tumor-infiltrating T cells are a favorable prognostic biomarker in HPV-associated head and neck cancer. Cancer Res. 2013, 73, 128-138.
34. Seiwert, T.; Burtness, B.; Weiss, J.; Gluck, I.; Eder, J.; Pai, S. A phase Ib study of MK-3475 in patients with human papillomavirus (HPV)-associated and non-HPV-associated head and neck (H/N) cancer. J. Clin. Oncol. 2014, 32, 132361-132144.